Compare LMB & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMB | KURA |
|---|---|---|
| Founded | 1901 | 2014 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 917.0M | 841.6M |
| IPO Year | 2014 | 2015 |
| Metric | LMB | KURA |
|---|---|---|
| Price | $74.77 | $10.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $116.67 | $25.56 |
| AVG Volume (30 Days) | 183.8K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.68 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $646,804,000.00 | $67,482,000.00 |
| Revenue This Year | $15.96 | $28.28 |
| Revenue Next Year | $5.90 | $106.37 |
| P/E Ratio | $205.08 | ★ N/A |
| Revenue Growth | 24.68 | ★ 25.24 |
| 52 Week Low | $65.08 | $5.45 |
| 52 Week High | $141.17 | $12.49 |
| Indicator | LMB | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 47.76 |
| Support Level | $70.70 | $8.53 |
| Resistance Level | $85.28 | $10.97 |
| Average True Range (ATR) | 3.16 | 0.53 |
| MACD | -0.27 | -0.15 |
| Stochastic Oscillator | 29.60 | 3.74 |
Limbach Holdings Inc is a building systems solutions firm that designs, delivers, and maintains mechanical (heating, ventilation, and air conditioning), electrical, plumbing, and controls (MEPC) systems. The Company partners with owners and operators of facilities across healthcare, industrial and manufacturing, data centers, life sciences, higher education, and cultural and entertainment markets. It operates through two segments: Owner Direct Relationships (ODR), which generates maximum revenue and includes owner direct projects, maintenance, and service on MEPC systems; and General Contractor Relationships (GCR), which manages new construction or renovation projects involving MEPC systems awarded by general contractors or construction managers.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.